A skin permeability barrier is essential for terrestrial animals, and its impairment causes several cutaneous disorders such as ichthyosis and atopic dermatitis. Although acylceramide is an important lipid for the skin permeability barrier, details of its production have yet to be determined, leaving the molecular mechanism of skin permeability barrier formation unclear.
Introduction
A skin permeability barrier protects terrestrial animals from inside the body, penetration of external soluble materials, and infection by pathogenetic organisms. In the stratum corneum, the outermost cell layer of the epidermis, multiple lipid layers (lipid lamellae) play a pivotal function in barrier formation (Fig. S1) (1-3) . Impairment of the skin permeability barrier leads to several cutaneous disorders, such as ichthyosis, atopic dermatitis, and infectious diseases.
The major components of the lipid lamellae are ceramide (the sphingolipid backbone), cholesterol, and free fatty acid (FA). In most tissues, ceramide consists of a long-chain base (LCB; usually sphingosine) and an amide-linked FA with a chain length of 16-24 (C16-C24) (4, 5) . On the other hand, ceramide species in the epidermis are strikingly unique (Fig. S2A ).
For example, epidermal ceramides contain specialized LCBs (phytosphingosine and 6-hydroxysphingosine) and/or FAs with α-or ω-hydroxylation (1-3). In addition, substantial amounts of epidermal ceramides have ultra long-chain (ULC) FAs (ULCFAs) with ≥C26 (4, 5). The most unique epidermal ceramides are acylceramides having C28-C36 ULCFAs, which are ω-hydroxylated and esterified with linoleic acid (EOS in Fig. S1 ; EODS, EOS, EOP, and EOH in Fig. S2A ) (1-3, 6, 7) . These characteristic molecules may be important to increase the hydrophobicity of lipid lamellae and/or to stabilize the multiple lipid layers.
Linoleic acid is one of the essential FAs, and its deficiency causes ichthyosis symptoms due to a failure to form normal acylceramide (8) . Ichthyosis is a cutaneous disorder accompanied by dry, thickened, and scaly skin; it is caused by a barrier abnormality. In atopic dermatitis patients, both total ceramide levels and the chain length of ceramides are decreased, and ceramide composition is also altered (9-11).
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In addition to its essential function in the formation of lipid lamellae, acylceramide is also important as a precursor of protein-bound ceramide, which functions to connect lipid lamellae and corneocytes ( Fig. S1) (12, 13) . After removal of linoleic acid, the exposed ω-hydroxyl group of acylceramide is covalently bound to corneocyte proteins, forming a corneocyte lipid envelope. Acylceramides and protein-bound ceramides are important in epidermal barrier formation, and mutations in the genes involved in their synthesis, including CERS3, ALOX12B, and ALOXE3, can cause non-syndromic, autosomal recessive congenital ichthyosis (ARCI) (3, (14) (15) (16) . The ceramide synthase CERS3 catalyzes the amide bond formation between an LCB base and ULCFA, producing ULC-ceramide, which is the precursor of acylceramide ( Fig. S1 and Fig. S2B ) (17) . The 12(R)-lipoxygenase ALOX12B and epidermal lipoxygenase-3 ALOXE3 are required for the formation of protein-bound ceramides (13, 18) . Other ARCI genes include the ATP-binding cassette (ABC) transporter ABCA12, the transglutaminase TGM1, NIPAL4/ICHTHYIN, CYP4F22/FLJ39501, LIPN, and PNPLA1 (16, 19) . The exact functions of NIPAL4, LIPN, and PNPLA1 are currently unclear.
Causative genes of syndromic forms of ichthyosis also include a gene required for acylceramide synthesis: the FA elongase ELOVL4, which produces ULCFA-CoAs, the substrate of CERS3 (20) .
Although acylceramide is essential for the epidermal barrier function, the mechanism behind acylceramide production is still poorly understood, leaving the molecular mechanisms behind epidermal barrier formation unclear. For example, acylceramide production requires ω-hydroxylation of the FA moiety of ceramide. However, the ω-hydroxylase responsible for this reaction has been heretofore unidentified (Fig. S1 ). Here, we identified the cytochrome P450 CYP4F22, also known as FLJ39501, as this missing FA ω-hydroxylase required for acylceramide production. CYP4F22 had been identified as one of the ARCI genes (21), 6 although its function in epidermal barrier formation remained unsolved. Our findings clearly demonstrate a relationship between ARCI pathology, acylceramide levels, and ω-hydroxylase activity. It has been reported that the cytochrome P450 (CYP) inhibitor aminobenzotriazole inhibits the generation of ω-hydroxyceramide in cultured human keratinocytes (22) . In humans, 57 CYP genes exist, and mammalian CYP genes are classified into 18 families and 43 subfamilies. Some CYP4F members are implicated in the ω-hydroxylation of long-chain FAs (23, 24) , raising the possibility that certain CYP4F subfamily members are responsible for ω-hydroxylation of ULCFAs in acylceramide formation. To test this possibility, we 8 cloned all of the human CYP4F subfamily genes (CYP4F2, 3A, 3B, 8, 11, 12, and 22) , and each was expressed as an N-terminally 3xFLAG-tagged protein in HEK 293T cells overproducing 3xFLAG-ELOVL4 and 3xFLAG-CERS3. All CYP4F subfamily proteins were expressed at similar levels ( Fig. 2A) . Among the CYP4F subfamily members, only CYP4F22 caused the disappearance of ULC-ceramide, which was concomitant with the production of a new band at the position of ω-hydroxyceramide ( Fig. 2B and Fig. S4 ). LC-MS analysis determined that this band indeed represented ω-hydroxyceramides with C28-C36 ( Fig. S5 ). Thus, CYP4F22 is the ω-hydroxylase required for ω-hydroxyceramide production.
Results

Identification
Correlation between CYP4F22 Activity and Ichthyosis Pathology
Although CYP4F22 gene has been identified as one of the ARCI-causative genes (21, 25) , its function in epidermal barrier formation has remained unsolved. Five missense mutations, which all cause amino acid substitutions (F59L, R243H, R372W, H435Y, and H436D), have been found in the CYP4F22 of ichthyosis patients. To examine their role in ichthyosis pathology, we introduced these mutations into CYP4F22 and examined the ω-hydroxylase activity of the resultant mutant proteins. All mutant proteins were expressed at equivalent levels to the wild type protein (Fig. 3A) , and indeed all ω-hydroxylase activity of the mutant CYP4F22 proteins decreased to 4-20% of wild type protein activity (Fig. 3B ). Therefore, protein activity and ichthyosis pathology were nicely correlated.
That being noted, ichthyosis due to CYP4F22 mutation is quite rare. In fact, a mere ~20
patients have been reported in Mediterranean populations (21) , and only a single patient in Japan (25) . The Japanese patient has compound heterozygous CYP4F22 mutations: one is a point mutation (c.728G>A) causing amino acid substitution (p.R243H; R243H) and the other is a deletion (c.1138delG) causing a frame shift (p.D380TfsX2; D380TfsX2), in which Asp380 is substituted to Thr followed by a stop codon (25) . The mutant R243H exhibited the decreased activity as described above (Fig. 3B) . We also introduced the c.1138delG mutation into CYP4F22 and examined the ω-hydroxylase activity of its truncated protein product.
D380TfsX2 (predicted molecular mass, 44.8 kDa) migrated faster than the wild type protein (62.0 kDa, Fig. 3A ), and we found that it exhibited no activity (Fig. 3B ).
To confirm our conclusion that CYP4F22 is involved in the production of acylceramide through ω-hydroxyceramide synthesis, we subjected the stratum corneum of the Japanese patient ( Fig. 3C) , as well as those of controls (her parents and a healthy volunteer), to LC-MS analysis and examined the levels of 11 major ceramide species. Although statistical analysis
could not be performed due to the low number of samples, all three acylceramides containing sphingosine (EOS), 6-hydroxysphingsoine (EOH), and phytosphingosine (EOP) were apparently decreased in the ARCI patient compared to the controls (to <1/10) ( Fig. 3D and Table S1 ). Instead, the non-acylated ceramides NS (which are a combination of sphingosine and a non-hydroxylated FA) and AS (which are a combination of sphingosine and an α-hydroxylated FA) seemed to be increased (Table S1 ). These results confirm that ω-hydroxyceramide production by CYP4F22 is indeed required for acylceramide synthesis.
CYP4F22 Is a Type I Endoplasmic Reticulum Membrane Protein
We next examined the subcellular localization of CYP4F22 by subjecting 3xFLAG-tagged CYP4F22 to indirect immunofluorescence microscopy ( Fig. 4A ). 3xFLAG-CYP4F22 exhibited a reticular localization pattern and was co-localized with calnexin, HA-ELOVL4, and HA-CERS3, all of which are endoplasmic reticulum (ER) proteins, indicating CYP4F22
is localized in the ER. A hydropathy plot showed that CYP4F22 contains a highly 10 hydrophobic region at the N-terminus as well as some weak hydrophobic stretches (Fig. 4B) .
To reveal the membrane topology of CYP4F22, we introduced a N-glycosylation cassette, which is N-glycosylated when exposed to the lumen of the ER, into several positions of CYP4F22, the N-terminus, E85/K (between Glu85 and Lys86 residues), H155/R, A285/L, C361/R, D455/N, and R508/K. Among these fusion proteins, only CYP4F22 containing the N-glycosylation cassette at the N-terminus received glycosylation, as the molecular weight shift was observed upon treatment with endoglycosidase H (Fig. 4C ). This result indicates that CYP4F22 spans the ER membrane once. Furthermore, it oriented its N-terminus to the ER lumen and the large, hydrophilic C-terminal domain containing the active site to the cytosolic side of the ER membrane. The same membrane topology was determined for other CYP members by the detection of N-terminal N-glycosylation (26, 27) .
When the N-terminal hydrophobic region was removed, the resulting CYP4F22ΔN became distributed throughout the cytoplasm (Fig. 4D) . CYP4F22ΔN was fractionated into both the soluble and membrane fractions by ultracentrifugation, in contrast to full-length CYP4F22, which was detected only in the membrane fraction (Fig. 4E) . These results confirmed that CYP4F22 is a type I ER membrane protein. CYP4F22ΔN could not produce ω-hydroxyceramide (Fig. 4F) , suggesting that anchoring to the ER membrane, where all of the reactions of acylceramide synthesis occur, is crucial for the CYP4F22 function.
ULCFAs Are Substrates of CYP4F22
It was still unclear whether CYP4F22 introduces a ω-hydroxyl group into ULCFAs before or after formation of ceramide. Therefore, we examined ω-hydroxy FA levels using LC-MS in the presence of the ceramide synthase inhibitor fumonisin B 1 . If ω-hydroxylation occurs prior to ceramide production, it was expected that free ω-hydroxy FA levels should be increased with fumonisin B 1 treatment. We found that ω-hydroxy FA levels with C26-C36 were significantly increased by addition of fumonisin B 1 (Fig. 5A) , suggesting that ω-hydroxylation occurs prior to ceramide production. Thus, it is highly likely that the substrates of CYP4F22 are not ceramides but rather FAs, the same type of substrate as catalyzed by other CYP4F family members.
To confirm that the substrates of CYP4F22 are FAs, we performed an in vitro analysis utilizing yeast, which has no endogenous FA ω-hydroxylase activity. When C30:0 FA was used as a substrate, the total membrane fractions prepared from yeast bearing a vector plasmid exhibited FA ω-hydroxylase activity only at the background levels (Fig. 5B ). On the other hand, the ectopic expression of human CYP4F22 resulted in the production of ω-hydroxy FA in an NADPH-dependent manner ( and CERS3, C26 ceramide; and ELOVL4 and CERS3, ≥C26 ceramides) (Fig. 5C ) (28, 29) .
Mammals have six ceramide synthases (CERS1-6) and seven FA elongases (ELOVL1-7), and each exhibits characteristic substrate specificity (Fig. S2B) (2, 4, 5, 28) . When CYP4F22 was expressed in these cells producing different ceramide species, ω-hydroxyceramides were produced in cells producing C26 ceramide (ELOVL1/CERS3 combination) and ≥C26
ceramides (ELOVL4/CERS3 combination) but not in cells producing C22-C24 ceramides
12
(ELOVL1/CERS2 combination) (Fig. 5D ). These results suggest that CYP4F22 can ω-hydroxylate ULCFAs (≥C26) but not VLCFAs (C22 and C24). The levels of ω-hydroxyceramide produced in ELOVL1/CERS3 cells were similar to those in ELOVL4/CERS3 cells, although the levels of non-hydroxyceramide substrates were much higher in ELOVL1/CERS3 cells. Thus, CYP4F22 exhibits especially high activity toward ULCFAs with ≥C28.
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Discussion
Here we identified CYP4F22 as an ULCFA ω-hydroxylase involved in acylceramide production. Acylceramide is quite important for epidermal barrier formation, and impairment of its production such as by ELOVL4 and CERS3 mutations causes ichthyosis (15, 20) .
CYP4F22 was first identified as an ARCI-causative gene by Fischer and her co-workers (21).
They proposed that CYP4F22 and most other ichthyosis-causative genes are involved in a We determined the membrane topology of CYP4F22 (Fig. 4C) , which indicates that the large C-terminal hydrophilic domain including catalytic residues is located in the cytosol.
Therefore, ω-hydroxylation of the ULCFA portion of acylceramide must occur on the cytosolic side of the ER membrane. Based on this finding, we propose a working model for the process of acylceramide production in the ER membrane as follows (Fig. S6) . Elongation of palmitoyl-CoA to ULCFA-CoA occurs on the cytoplasmic side of the ER membrane.
Since lipids comprising the ER membrane are mostly C16 and C18, ULCFA (C28-C36)
portions of ULCFA-CoAs should be bent in the cytosolic leaflet of the ER membrane (Fig.   S6 ) or be penetrated into the luminal leaflet. Although the latter possibility cannot be excluded, we prefer the former possibility, since in the latter model ULCFA must 'flip-flop'
at least three times in the ER membrane in the course of acylceramide production. Since the substrates of CYP4F22 are ULCFAs (Fig. 5 ), ULCFA-CoAs should be converted to ULCFAs before ω-hydroxylation. After ω-hydroxylation of ULCFAs by CYP4F22, the resulting ω-hydroxy-ULCFA is converted to ω-hydroxy-ULCFA-CoA by acyl-CoA synthetase.
ACSVL4/FATP4 is the candidate acyl-CoA synthetase for this reaction, since Acsvl4 mutant mice exhibited skin barrier defects (32) . CERS3 catalyzes formation of ω-hydroxyceramide from ω-hydroxy-ULCFA-CoA and LCB. An unknown acyltransferase then introduces linoleic acid into the ω-hydroxy group of ω-hydroxyceramide, generating acylceramide.
Our results presented here demonstrated for the first time that CYP4F22 is a bona fide ULCFA ω-hydroxylase required for acylceramide production. Our findings provide important new insights into the molecular mechanisms of skin permeability barrier formation.
Future development of compounds that strengthen the skin permeability barrier by increasing acylceramide-synthetic proteins such as ELOVL4, CERS3, and CYP4F22 may be useful for treatment of cutaneous disorders including ichthyosis and atopic dermatitis.
Materials and Methods
Detailed materials and methods used for all procedures are available in SI Text. 
Immunoblotting
Immunoblotting was performed as described previously (34, 35) A.K. planned the project, designed the experiments, and wrote the manuscript.
The authors declare no conflict of interest. were transfected with pCE-puro 3xFLAG-CYP4F22, pCE-puro 3xFLAG-CYP4F22 (N-term, insertion of the N-glycosylation cassette to the N-terminus), pCE-puro 3xFLAG-CYP4F22
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(E85/K, insertion of the cassette between Glu-85 and Lys-86), pCE-puro 3xFLAG-CYP4F22 (H155/R), pCE-puro 3xFLAG-CYP4F22 (A285/L), pCE-puro 3xFLAG-CYP4F22 (C361/R), pCE-puro 3xFLAG-CYP4F22 (D455/N), or pCE-puro 3xFLAG-CYP4F22 (R508/K).
Lysates (3 μg) prepared from transfected cells were treated with or without endoglycosidase H (Endo H) and separated by SDS-PAGE, followed by immunoblotting with anti-FLAG antibodies. (E) Total cell lysates (10 μg) were centrifuged at 100,000 x g for 30 min at 4 ºC.
The resulting supernatant (soluble fraction; S) and pellet (membrane fraction; M) were subjected to immunoblotting using anti-FLAG, anti-calnexin (membrane protein marker), or anti-GAPDH (soluble protein marker) antibodies. IB, immunoblotting. (F) HEK 293T cells transfected with plasmids encoding 3xFLAG-ELOVL4, 3xFLAG-CERS3, and 3xFLAG-
